Reflektion is a company.
Reflektion has raised $10.0M across 2 funding rounds.
Key people at Reflektion.
Reflektion was founded by Amar Chokhawala (Founder / CEO).
Reflektion has raised $10.0M in total across 2 funding rounds.
Reflektion was founded by Amar Chokhawala (Founder / CEO).
Reflektion has raised $10.0M in total across 2 funding rounds.
Reflektion's investors include ENIAC Ventures, Footwork, Great Oaks Venture Capital, Shasta Ventures, Slow Ventures, Matt Mazzeo, Prashant Malik, Clear Ventures.
RefleXion Medical is a privately-held medical technology company that develops biologically-guided radiation therapy (BgRT) systems for cancer treatment. Its flagship product, the RefleXion X1 machine, integrates PET imaging with radiotherapy to precisely target multiple tumors, including those in motion, enabling treatment of advanced-stage cancers such as metastatic (stage 4) disease. The company serves cancer patients and oncology providers by addressing the challenge of efficiently and accurately treating multiple tumors in a single session, aiming to improve outcomes and patient experience. RefleXion has demonstrated significant growth momentum through clinical validation, strategic partnerships, and commercial sales of its X1 system[3][4][8].
RefleXion was founded by Sam Mazin and Akshay Nanduri after a conversation at Stanford University about leveraging cancer’s biology to simultaneously see and treat multiple tumors. This idea led to the invention of BgRT, a novel approach combining medical physics, nuclear medicine, and radiotherapy. The company was officially formed in Hayward, California, and quickly advanced through clinical research, assembling a multidisciplinary scientific advisory board and publishing foundational peer-reviewed work. Early traction included the first sale of the RefleXion X1 machine in 2020 to a leading academic medical center, marking a pivotal milestone in commercializing their innovative cancer treatment technology[3][4].
RefleXion rides the trend of precision oncology and the integration of advanced imaging with therapeutic technologies. The timing is critical as cancer treatment increasingly demands personalized, targeted approaches to improve survival and quality of life, especially for metastatic disease. Market forces such as rising cancer incidence, demand for better treatment modalities, and advances in imaging and AI favor RefleXion’s BgRT approach. By pioneering this convergence of biology and radiotherapy, RefleXion influences the broader oncology ecosystem, potentially setting new standards for cancer care and inspiring further innovation in biologically guided therapies[3][4].
Looking ahead, RefleXion aims to expand the adoption of its BgRT technology globally, refine its clinical applications, and broaden its impact on metastatic cancer treatment. Trends shaping its journey include advances in molecular imaging, AI-driven treatment planning, and growing emphasis on value-based care in oncology. As the company scales, its influence may grow from a niche innovator to a mainstream cancer treatment provider, potentially transforming radiotherapy paradigms and improving outcomes for patients with complex cancer presentations. The company’s trajectory exemplifies how cutting-edge technology can translate scientific insight into life-saving medical solutions[3][4][8].
Key people at Reflektion.
Reflektion has raised $10.0M across 2 funding rounds. Most recently, it raised $8.0M Series A in March 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2014 | $8.0M Series A | ENIAC Ventures, Footwork, Great Oaks Venture Capital, Shasta Ventures, Slow Ventures, Matt Mazzeo, Prashant Malik | |
| Apr 1, 2013 | $2.0M Seed | Clear Ventures |
